[breadcrumb_custom]

Pacific Biosciences of California Inc Inc. (PACB) Price Performance: A Fundamental Analysis Perspective

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -32.31%. However, over the last six months, the performance has been stronger by -44.25%. The price of PACB decreased -16.58% over the last 30 days. And in the last five days, it has fallen by -1.63%.

Pacific Biosciences of California Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $14.55 on 07/18/23, while the lowest price for the same period was registered at $5.74 on 11/01/23.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

52-week price history of PACB Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Pacific Biosciences of California Inc’s current trading price is -54.36% away from its 52-week high, while its distance from the 52-week low is 15.68%. The stock’s price range during this period has varied between$5.74 and $14.55. The Pacific Biosciences of California Inc’s shares, which operate in the Healthcare, saw a trading volume of around 6.79 for the day, a figure considerably higher than their average daily volume of 1.31 over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Pacific Biosciences of California Inc (PACB) has experienced a quarterly decline of -0.75% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.78B.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 7.95, with a change in price of -3.04. Similarly, Pacific Biosciences of California Inc recorded 6,161,021 in trading volume during the last 100 days, posting a change of -31.40%.

PACB’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 1.22. Similarly, the long-term debt-to-equity ratio is also 1.21.

PACB Stock Stochastic Average

As of today, Pacific Biosciences of California Inc’s raw stochastic average for the last 50 days stands at 13.58%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 42.28%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 28.06% and 22.32%, respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts